Why the study?
There are no licensed vaccines or therapeutics for human noroviruses, and a lack of well-characterized infection models has limited countermeasure development.
Provides a summary of available experimental models and reverse genetic systems for Human Norovirus research to aid in vaccine and therapeutic development.
Animal models may accelerate HuNoV countermeasure development; leaves open human translation and efficacy.
Human noroviruses (HuNoVs) are a leading cause of acute gastroenteritis worldwide. HuNoV infections lead to substantial societal and economic burdens. There are currently no licensed vaccines or therapeutics for the prevention or treatment of HuNoVs. A lack of well-characterized in vitro and in vivo infection models has limited the development of HuNoV countermeasures. Experimental infection of human volunteers and the use of related viruses such as murine NoV have provided helpful insights into HuNoV biology and vaccine and therapeutic development. There remains a need for robust animal models and reverse genetic systems to further HuNoV research. This review summarizes available HuNoV animal models and reverse genetic systems, while providing insight into their usefulness for vaccine and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Todd et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: